When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated ...
Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo ...
Novo Nordisk scientist Lotte Knudsen, whose research led to Ozempic and Wegovy, started her career developing laundry ...
Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide— while adding great ...
Those market dynamics will again be in focus when Novo reports results for its diabetes drug Ozempic and weight-loss medicine ...
It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...
Ascendis Pharma will license its TransCon technology to Novo to develop therapies for metabolic and cardiovascular diseases.
Novo's development chief, Martin Holst Lange, has shown optimism about the drug's promise, though he refrained from making ...
A more tragic irony in the town is an obesity crisis among residents living in the shadow of the massive Wegovy-making plant.
“We do not condone these practices and it’s important to understand that for Ozempic, only the marked doses on the pens (0.25 ...
Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...
Novo Nordisk reports earnings Wednesday morning, with sales of blockbuster weight-loss drugs Ozempic and Wegovy expected to continue driving the Danish drugmaker's results higher.